Epidemiology of Genital Herpes

Much has been learned in the last decade about the epidemiology of genital herpes infections, including new information about seroprevalence and the risk of transmission of genital herpes to sex partners and at delivery. The type-specific serologic assays now routinely used in these studies are not widely available, and commercially available assays that claim to be type-specific are not.

Thus, most clinicians still do not have access to reliable type-specific assays. In cross-sectional seroprevalence studies, detection of HSV-2 antibody is positively associated with increasing age, lower levels of income or education, increased numbers of sexual partners, black or Hispanic race, female gender, male homosexual activity, and HIV infection.

In addition, studies have clarified the clinical spectrum of genital herpes infection in persons who have transmitted genital herpes to a sex partner, have shed virus asymptomatically, or are found to have HSV-2 antibody. Ten percent to 40% of these individuals are aware that they have genital herpes, whereas the remaining 60% to 90% are not.

Among the latter, at least half have a history of recurrent genital lesions typical of genital herpes or can be taught to recognize typical, symptomatic episodes within 6 months if examined promptly after the onset of any unexplained genital symptoms. The remainder, about a third of the total, have no history of genital herpes and remain asymptomatic despite a careful history and follow-up examinations; in women in this group, asymptomatic shedding of HSV can be identified.

Atypical lesions appear to play an important but as yet incompletely defined role. Most persons who transmit genital herpes to a sex partner or at delivery do not have a history of lesions at the time of transmission of HSV infection, suggesting that asymptomatic shedding or atypical, unrecognized lesions are responsible for most cases of transmission.

In heterosexual couples, the risk of acquisition of HSV-2 infection from a sex partner with genital herpes is lowest in men, higher in HSV-1 seropositive women, and highest in women without antibody to HSV-1 or HSV-2. The risk of transmission to infants exposed to asymptomatic shedding at delivery is low in women with or without a history of genital herpes if HSV antibody of the same type is present in cord blood.

The HSV is highly contagious. Although there are eight different strains, HSV1 and HSV2 are responsible for the majority of herpes infections. The cure for herpes symptoms is dependent on which strain of the virus is contracted. Cures for herpes only relieve the symptoms but do not eradicate the virus. Herpes cures are being developed but so far, the window of opportunity for their effective use is small.

After a person becomes infected with HSV, the virus moves to sensory nerves in the ganglia. Once there, it seems to reside, at which point herpes cure is no longer feasible. Finding the cure for herpes is really tough. Unlike HPV (the virus that causes warts), which is satisfied and content with simply nestling into skin tissue, the herpes virus opts to burrow deep into the system. Cures for herpes would have to do the same.

HSVCurative is a potent all natural antiviral cure for herpes, highly effective against HSV1 and HSV2; it has a wide spectrum of antiviral activity against these viruses, even for genital herpes. The cure in this treatment has the ability to inactivate and destroy HSV, which has been established in published clinical trials. It is to be applied directly to an outbreak.

HSVCurative is used specifically to treat HSV1 and HSV2 infections and acts as a curative agent against both these strains of herpes. It exhibits a pronounced anti-herpetic activity against HSV1 and HSV2 and, unlike other cures for herpes, actually kills these viruses upon exposure regardless of location on the body.

HSVCurative is formulated at maximum strength and has produced spectacular results above other potential herpes cures in eliminating herpes outbreaks in almost all known cases of use on herpes. It is possibly the most powerful and effective topical herpes treatment on the market, providing total clearance of outbreaks time after time.

Topical application causes herpes outbreaks to dissolve and dry out, with total clearance commonly experienced in 24 to 36 hours. This herpes cure gives immediate results and pain relief are certainly experienced with every application. To learn more, please go to http://www.bcured.net.